{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192"}]}],"title":"Number of Ocular Symptoms reported"},{"categories":[{"measurements":[{"groupId":"OG000","value":"102"}]}],"title":"Blurry Vision"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"Dry Eyes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"Photophobia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"Other"}],"denomUnitsSelected":"Ocular Symptoms","denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"192"}],"units":"Ocular Symptoms"}],"description":"Study procedures included recording ocular symptoms reported by patients documented in the clinic notes. These were categorized into blurry vision, dry eyes, photophobia and other symptoms (including foreign-body sensation, \"grittiness\", \"itch/scratchiness\", irritation, and tearing). This Data table reports the total number of Ocular Symptoms reported by patients, along with counts and percentage by type of symptom.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_UNITS","populationDescription":"The 30 patients in the study reported specific symptoms a total of 192 times at clinic visits. The analysis population is the 192 symptoms reported.","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Ophthalmology: Number of Ocular Symptoms Reported","type":"POST_HOC","typeUnitsAnalyzed":"Ocular Symptoms","unitOfMeasure":"Ocular Symptoms"}